Pulmonary hypertension: Old targets revisited (Statins, PPARs, Beta-Blockers)

Handbook of Experimental Pharmacology

Volumn 218, Issue , 2013, Pages 531-548

  Watson, Geoffrey ^a   Oliver, Eduardo ^a   Zhao, Lan ^a   Wilkins, Martin R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Betablockers; Drug targets; PPARs; Repurposing; Statins; Treatment

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; ACETYLSALICYLIC ACID; AROTINOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CYTOCHROME P450 3A4; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PLACEBO; PRAZOSIN; PROPRANOLOL; ROSIGLITAZONE; SILDENAFIL; SIMVASTATIN;

ARTERIOLE; ARTICLE; CLINICAL EVALUATION; DRUG EFFECT; DRUG EFFICACY; HEART PROTECTION; HEART RIGHT VENTRICLE FUNCTION; HUMAN; MOLECULAR MECHANICS; NONHUMAN; OUTCOME ASSESSMENT; PATHOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; PPAR GAMMA;

EID: 84893089417     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-38664-0-21     Document Type: Article

References (86)

1. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshit A (2004) Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94:385-393
2. Alastalo TP, Li M, Perez VJ, Pham D, Sawada H, Wang JK, Koskenvuo M, Wang L, Freeman BA, Chang HY, Rabinovitch M (2011) Disruption of PPARgamma/beta-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest 121:3735-3746
3. Ali OF, Growcott EJ, Butrous GS, Wharton J (2011) Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells. Respir Res 12:137
4. Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, Gardai SJ, Wick M, Nemenoff RA, Geraci MW, Voelkel NF (2003) Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 92:1162-1169
5. Bartel DP (2004) MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297
6. Bogaard HJ, Abe K, Vonk NA, Voelkel NF (2009) The right ventricle under pressure: Cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 135:794-804
7. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN, Voelkel NF (2010) Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 182:652-660
8. Bristow MR (2000) Beta-adrenergic receptor blockade in chronic heart failure. Circulation 101:558-569
9. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S et al (1986) Beta 1-and beta 2-adrenergic- receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59:297-309
10. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, Trendelenburg U (1994) International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121-136
11. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM (2003) Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23:52-57
12. Committee NRN (1999) A unified nomenclature system for the nuclear receptor superfamily. Cell 97:161-163
13. Crossno JT Jr, Garat CV, Reusch JE, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR, Klemm DJ (2007) Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 292:L885-L897
14. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT et al (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:343-349
15. de Dios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GL, Law RE, Little PJ (2003) Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 107:2548-2550
16. de Man FS, Handoko ML, van Ballegoij JJ, Schalij I, Bogaards SJ, Postmus PE, van der Velden J, Westerhof N, Paulus WJ, Vonk-Noordegraaf A (2012) Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail 5:97-105
17. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, McMurtry IF (2004) Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 287:L656-L664
18. Frishman WH (2008) beta-Adrenergic blockers: A 50-year historical perspective. Am J Ther 15:565-576
19. Fujio H, Nakamura K, Matsubara H, Kusano KF, Miyaji K, Nagase S, Ikeda T, Ogawa A, Ohta-Ogo K, Miura D, Miura A, Miyazaki M, Date H, Ohe T (2006) Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 47:250-255
20. Gaemperli O, Liga R, Spyrou N, Rosen SD, Foale R, Kooner JS, Rimoldi OE, Camici PG (2010) Myocardial beta-adrenoceptor down-regulation early after infarction is associated with longterm incidence of congestive heart failure. Eur Heart J 31:1722-1729
21. Gauthier C, Tavernier G, Charpentier F, Langin D, Le MH (1996) Functional beta3-adrenoceptor in the human heart. J Clin Invest 98:556-562
22. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, Balligand JL, Le MH (1998) The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102:1377-1384
23. Girgis RE, Li D, Zhan X, Garcia JG, Tuder RM, Hassoun PM, Johns RA (2003) Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 285: H938-H945
24. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425-430
25. Gong K, Xing D, Li P, Aksut B, Ambalavanan N, Yang Q, Nozell SE, Oparil S, Chen YF (2011) Hypoxia induces downregulation of PPAR-gamma in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor-beta signaling. Am J Physiol Lung Cell Mol Physiol 301:L899-L907
26. Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, Lirussi F, Bardou M (2006) The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotalineinduced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol 373:401-414
27. Harrington LS, Moreno L, Reed A, Wort SJ, Desvergne B, Garland C, Zhao L, Mitchell JA (2010) The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. PLoS One 5:e9526
28. Heresi GA, Aytekin M, Newman J, DiDonato J, Dweik RA (2010) Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med 182:661-668
29. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El AD, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and wellbeing in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283:1295-1302
30. Hu H, Sung A, Zhao G, Shi L, Qiu D, Nishimura T, Kao PN (2006) Simvastatin enhances bone morphogenetic protein receptor type II expression. Biochem Biophys Res Commun 339:59-64
31. Hyvelin JM, Howell K, Nichol A, Costello CM, Preston RJ, McLoughlin P (2005) Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 97:185-191
32. Ishikawa M, Sato N, Asai K, Takano T, Mizuno K (2009) Effects of a pure alpha/beta-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats. Circ J 73:2337-2341
33. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86
34. Joshi SR, McLendon JM, Comer BS, Gerthoffer WT (2011) MicroRNAs-control of essential genes: Implications for pulmonary vascular disease. Pulm Circ 1:357-364
35. Kao PN (2005) Simvastatin treatment of pulmonary hypertension: An observational case series. Chest 127:1446-1452
36. Kawut SM, Bagiella E, Lederer DJ, Shimbo D, Horn EM, Roberts KE, Hill NS, Barr RG, Rosenzweig EB, Post W, Tracy RP, Palevsky HI, Hassoun PM, Girgis RE (2011) Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 123:2985-2993
37. Kim EK, Lee JH, Oh YM, Lee YS, Lee SD (2010) Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats. Respirology 15:659-668
38. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004-1010
39. Ladage D, Schwinger RH, Brixius K (2013) Cardio-selective beta-blocker: Pharmacological evidence and their influence on exercise capacity. Cardiovasc Ther 31(2):76-83. doi:10.1111/j1755-5922.2011.00306x
40. Laudi S, Trump S, Schmitz V, West J, McMurtry IF, Mutlak H, Christians U, Weimann J, Kaisers U, Steudel W (2007) Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol 293:L630-L638
41. Laufs U, Fata VL, Liao JK (1997) Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272:31725-31729
42. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C (2004) Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 25:1341-1362
43. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099
44. Mandard S, Muller M, Kersten S (2004) Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61:393-416
45. Matsuda Y, Hoshikawa Y, Ameshima S, Suzuki S, Okada Y, Tabata T, Sugawara T, Matsumura Y, Kondo T (2005) Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats. Nihon Kokyuki Gakkai Zasshi 43:283-288
46. Maurer-Stroh S, Koranda M, Benetka W, Schneider G, Sirota FL, Eisenhaber F (2007) Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput Biol 3:e66
47. McDevitt DG (1987) Pharmacologic aspects of cardioselectivity in a beta-blocking drug. Am J Cardiol 59:10F-12F
48. McGowan CL, Swiston JS, Notarius CF, Mak S, Morris BL, Picton PE, Granton JT, Floras JS (2009) Discordance between microneurographic and heart-rate spectral indices of sympathetic activity in pulmonary arterial hypertension. Heart 95:754-758
49. McMurtry MS, Bonnet S, Michelakis ED, Bonnet S, Haromy A, Archer SL (2007) Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: The rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol 293: L933-L940
50. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL (2001) Upregulation of beta (3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103:1649-1655
51. Murata T, Kinoshita K, Hori M, Kuwahara M, Tsubone H, Karaki H, Ozaki H (2005) Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 25:2335-2342
52. Nagaoka T, Morio Y, Casanova N, Bauer N, Gebb S, McMurtry I, Oka M (2004) Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 287:L665-L672
53. Nisbet RE, Bland JM, Kleinhenz DJ, Mitchell PO, Walp ER, Sutliff RL, Hart CM (2010) Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol 42:482-490
54. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao PN (2002) Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 166:1403-1408
55. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN (2003) Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108:1640-1645
56. Niu X, Watts VL, Cingolani OH, Sivakumaran V, Leyton-Mange JS, Ellis CL, Miller KL, Vandegaer K, Bedja D, Gabrielson KL, Paolocci N, Kass DA, Barouch LA (2012) Cardioprotective effect of beta-3 adrenergic receptor agonism: Role of neuronal nitric oxide synthase. J Am Coll Cardiol 59:1979-1987
57. Nunes KP, Rigsby CS, Webb RC (2010) RhoA/Rho-kinase and vascular diseases: what is the link Cell Mol Life Sci 67:3823-3836
58. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658
59. Peacock A, Ross K (2010) Pulmonary hypertension: A contraindication to the use of {beta}-adrenoceptor blocking agents. Thorax 65:454-455
60. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H (2004) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 5:81-87
61. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM (2005) Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 25:1810-1816
62. Pott C, Brixius K, Bundkirchen A, Bolck B, Bloch W, Steinritz D, Mehlhorn U, Schwinger RH (2003) The preferential beta3-adrenoceptor agonist BRL 37344 increases force via beta1-/beta2-adrenoceptors and induces endothelial nitric oxide synthase via beta3-adrenoceptors in human atrial myocardium. Br J Pharmacol 138:521-529
63. Pott C, Steinritz D, Napp A, Bloch W, Schwinger RH, Brixius K (2006) On the function of beta3-adrenoceptors in the human heart: Signal transduction, inotropic effect and therapeutic prospects. Wien Med Wochenschr 156:451-458
64. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O (2006) Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 130:120-126
65. Reiter MJ, Reiffel JA (1998) Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 82:9I-19I
66. Robbins IM, Kawut SM, Yung D, Reilly MP, Lloyd W, Cunningham G, Loscalzo J, Kimmel SE, Christman BW, Barst RJ (2006) A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J 27:578-584
67. Sah VP, Seasholtz TM, Sagi SA, Brown JH (2000) The role of Rho in G protein-coupled receptor signal transduction. Annu Rev Pharmacol Toxicol 40:459-489
68. Sandoval J, Bauerle O, Palomar A, Gomez A, Martinez-Guerra ML, Beltran M, Guerrero ML (1994) Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89:1733-1744
69. Satoh K, Fukumoto Y, Nakano M, Sugimura K, Nawata J, Demachi J, Karibe A, Kagaya Y, Ishii N, Sugamura K, Shimokawa H (2009) Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res 81:226-234
70. Sgarra L, Addabbo F, Potenza MA, MontagnaniM(2012) Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: Molecular mechanisms in the context of integrated pathophysiology. Am J Physiol Endocrinol Metab 302:E1171-E1182
71. So PP, Davies RA, Chandy G, Stewart D, Beanlands RS, Haddad H, Pugliese C, Mielniczuk LM (2012) Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol 109:1504-1509
72. Somlyo AP, Somlyo AV (2003) Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: Modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83:1325-1358
73. Sun X, Ku DD (2008) Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol 294:H801-H809
74. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, Burns N, Kasper M, Voelkel NF (2006) Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 291:L668-L676
75. Tongers J, Schwerdtfeger B, Klein G, Kempf T, Schaefer A, Knapp JM, Niehaus M, Korte T, Hoeper MM (2007) Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 153:127-132
76. Tual L, Morel OE, Favret F, Fouillit M, Guernier C, Buvry A, Germain L, Dhonneur G, Bernaudin JF, Richalet JP (2006) Carvedilol inhibits right ventricular hypertrophy induced by chronic hypobaric hypoxia. Pflugers Arch 452:371-379
77. Turner NA, Midgley L, O'Regan DJ, Porter KE (2007) Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol 50:458-461
78. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database. BMJ 339:b4731
79. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, Boonstra A, Marques KM, Westerhof N, Vonk-Noordegraaf A (2011) Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 58:2511-2519
80. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P (2004) Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 110:1308-1312
81. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13:423-433
82. Voelkel NF, McMurtry IF, Reeves JT (1980) Chronic propranolol treatment blunts right ventricular hypertrophy in rats at high altitude. J Appl Physiol 48:473-478
83. Wang CY, Liu PY, Liao JK (2008) Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results. Trends Mol Med 14:37-44
84. Wilkins MR, Ali O, Bradlow W, Wharton J, Taegtmeyer A, Rhodes CJ, Ghofrani HA, Howard L, Nihoyannopoulos P, Mohiaddin RH, Gibbs JS (2010) Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med 181:1106-1113
85. Zeng WJ, Xiong CM, Zhao L, Shan GL, Liu ZH, Xue F, Gu Q, Ni XH, Zhao ZH, Cheng XS, Wilkins MR, He JG (2012) Atorvastatin in pulmonary hypertension (APATH) study. Eur Respir J 40(1):67-74
86. Zhao L, Sebkhi A, Ali O, Wojciak-Stothard B, Mamanova L, Yang Q, Wharton J, Wilkins MR (2009) Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J 34:948-957